A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2019
Price : $35 *
At a glance
- Drugs ANB 019 (Primary) ; ANB 019 (Primary)
- Indications Generalised pustular psoriasis
- Focus Adverse reactions; Therapeutic Use
- Acronyms GALLOP
- Sponsors AnaptysBio
- 30 Sep 2019 According to an AnaptysBio media release, based on the interim results the company is curtailing the washout period required prior to enrollment. Additional data form the trial is expeted during 2020.
- 30 Sep 2019 Interim results presented in the AnaptysBio media release.
- 08 Nov 2018 According to an AnaptysBio media release, data from this study is expected in mid 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History